

Use of a Nebulized LAMA for the Treatment of COPD

FOR PATIENTS




MYTH

BUSTED


Nebulizer therapy is only for use in the hospital.

People with COPD have used nebulizer therapy at home effectively for decades.¹



Nebulizer therapy at home is inconvenient and not worth the effort.

In surveys, most people with COPD who use home nebulizer therapy thought the benefit outweighed any inconvenience.²




Handheld inhalers are easy to use without mistakes.

Most people with COPD who use hand-held inhalers make errors in technique, even though they feel confident using the device.³

All handheld inhalers deliver medications into the lungs equally.

Delivery of medicine to the lungs varies greatly based on the type of device used.⁴



If you used an inhaler before and it "worked," you should always be able to use the same inhaler.

Older age and cognition have been shown to affect the ability to use a handheld inhaler properly.⁵

To learn more, go to chestfoundation.org

Developed by the American College of Chest Physicians with support from Viatrix and Theravance Biopharma.

Read the CHEST Foundation Patient Education disclosure at <http://foundation.chestnet.org/patient-education-disclosure>

09/00/21



MYTH

BUSTED

Even if you don't use an inhaler "perfectly," it's probably good enough.



Incorrect use of an inhaler is common and increases the chance of hospitalization and needing antibiotics or steroids.⁶

Nebulized medicines don't make a difference for quality of life.

In 400 random patient interviews, 75% of people using nebulized medications for COPD felt their quality of life improved.²

Not every type of COPD medicine is available in a nebulized form.

Every class of inhaled medication used for COPD is available in a nebulized form, including long-acting antimuscarinic agents (LAMAs).^{7,8}



References: 1. Global Initiative for Chronic Obstructive Lung Disease, 2021 GOLD Reports. https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf. 2. Sharafkhaneh A, et al. *COPD*. 2013;10(4): 482-492. 3. Souza ML, et al. *J Bras Pneumol*. 2009;35(9):824-831. 4. Hania NA, et al. *Chronic Obstr Pulm Dis*. 2018;5:111-123. 5. American Association for Respiratory Care. <https://www.aarc.org/wp-content/uploads/2018/01/aerosol-guide-for-hcp-3rd.pdf>. 6. Melani AS, et al. *Respir Med*. 2011;105(6):930-938. 7. Drugs.com. <https://www.drugs.com/history/lonhala-magnair.html>. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210598Orig1s000TOC.cfm. 8. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210598Orig1s000TOC.cfm.

To learn more, go to chestfoundation.org

Developed by the American College of Chest Physicians with support from Viatrix and Theravance Biopharma.

Read the CHEST Foundation Patient Education disclosure at <http://foundation.chestnet.org/patient-education-disclosure>

09/00/21

